PMID: 16518062Mar 7, 2006Paper

A pilot phase II study of capecitabine in advanced or recurrent breast cancer

Breast Cancer : the Journal of the Japanese Breast Cancer Society
Toshiaki SaekiTetsuo Taguchi

Abstract

A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer. A total of 23 patients who had received no more than one prior chemotherapy regimen received oral 828 mg/m2 capecitabine twice daily for 3 weeks followed by a 1-week rest period. The response to capecitabine was evaluated in 22 patients (one patient ineligible). The overall response rate was 45.5% (95% CI, 24.4-67.8%), including 1 complete response (4.5%) and 9 patients with partial response (40.9%). A further 7 patients (31.8%) had stable disease. The median duration of response was 7.2 months (range, 3.0-15.8 months) and the median time to progression was 6.4 months (95% CI, 4.1-15.1 months). Treatment-related adverse events >or= grade 3 were observed in 7 patients (30.1%). Intermittent capecitabine therapy (828 mg/m(2) twice daily for 3 weeks followed by a 1-week rest period) was shown to be effective and well tolerated as second-line treatment for advanced or recurrent breast cancer. The Japanese regimen is worthy of further study in larger numbers of patients in phase II / III clinical trials.

References

Jan 1, 1983·Chemical & Pharmaceutical Bulletin·A KonoH Ishitsuka
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R BudmanT Griffin
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Apr 5, 2001·Clinical Pharmacokinetics·B ReignerE Weidekamm
Jan 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M M BornerP Fumoleau
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Feb 25, 2005·International Journal of Clinical Oncology·Toshiaki SaekiTetsuo Taguchi

❮ Previous
Next ❯

Citations

Jul 21, 2007·Cancer Chemotherapy and Pharmacology·Norikazu MasudaUNKNOWN Kinki Breast Cancer Study Group (KBCSG)
Jul 28, 2009·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Mikihiro KusamaEisei Shin
Mar 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ZielinskiM Martin
Feb 24, 2011·Expert Review of Anticancer Therapy·H Cortes-Funes, I Ghanem
Aug 28, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M KaufmannUNKNOWN GBG-39 Trialists
Mar 20, 2010·Clinical Breast Cancer·Michael Naughton
Jun 2, 2007·NMR in Biomedicine·Torill E SjøbakkIngrid S Gribbestad
Feb 20, 2007·The International Journal of Biochemistry & Cell Biology·Sébastien RogerJean-Yves Le Guennec
Nov 8, 2008·Expert Opinion on Biological Therapy·Emilio BriaEdmondo Terzoli
Apr 9, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Nobuya KobashiYuji Kuge

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Emilio BajettaRoberto Buzzoni
The Breast : Official Journal of the European Society of Mastology
L El-Helw, R E Coleman
Breast Cancer : the Journal of the Japanese Breast Cancer Society
Mikihiro KusamaEisei Shin
© 2021 Meta ULC. All rights reserved